Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.

Proceedings of the National Academy of Sciences of the United States of America - 16 Apr 1996

Black M E, Newcomb T G, Wilson H M, Loeb L A

Abstract excerpt

Herpes simplex virus type 1 (HSV-1) thymidine kinase is currently used as a suicide agent in the gene therapy of cancer. This therapy is based on the preferential phosphorylation of nucleoside analogs by tumor cells expressing HSV-1 thymidine kinase. However, the use of HSV-1 thymidine kinase is limited in part by the toxicity of the nucleoside analogs. We have used random sequence mutagenesis to create new HSV-1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Sequence
Share to Base Sequence

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Line

Share to Escherichia coli

Share to Molecular Sequence Data

Share to Mutation

Share to Transfection

Source

Open in PubMed Open full text

Identifiers

PMID: 8622970
DOI: 10.1073/pnas.93.8.3525
PMCID: PMC39643

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.PMID 8622970Read ↗

Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity.Semantic proximity Read ↗

Identification of important residues within the putative nucleoside binding site of HSV-1 thymidine kinase by random sequence selection: analysis of selected mutants in vitro.Semantic proximity Read ↗

Selection of new biologically active molecules from random nucleotide sequences.Semantic proximity Read ↗

Mutation of herpesvirus thymidine kinase to generate ganciclovir-specific kinases for use in cancer gene therapies.Semantic proximity Read ↗

Random mutagenesis of the thymidine kinase gene of varicella-zoster virus.Semantic proximity Read ↗

A designed equine herpes thymidine kinase (EHV4 TK) variant improves ganciclovir-induced cell-killing.Semantic proximity Read ↗

Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant.Semantic proximity Read ↗

Engineering of a single conserved amino acid residue of herpes simplex virus type 1 thymidine kinase allows a predominant shift from pyrimidine to purine nucleoside phosphorylation.Semantic proximity Read ↗

Systematic exploration of active site mutations on human deoxycytidine kinase substrate specificity.Semantic proximity Read ↗

Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment.Semantic proximity Read ↗

Redesigning human 2'-deoxycytidine kinase enantioselectivity for L-nucleoside analogues as reporters in positron emission tomography.Semantic proximity Read ↗

Creation and characterization of 5-fluorodeoxyuridine-resistant Arg50 loop mutants of human thymidylate synthase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.